Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021,” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Chronic Hepatitis B Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic Hepatitis B Virus Infection: Overview
Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical and viral parameters that influence disease outcomes. In addition to liver biochemistry, virological markers, and abdominal ultrasonography, non-invasive assessment of liver fibrosis is emerging as an important assessment modality. Long-term nucleos(t)ide-analogue therapy is safe and well tolerated, achieves potent viral suppression, and reduces the incidence of liver-related complications. However, a need to optimise management remains. Promising novel therapies are at the developmental stage.
'Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Hepatitis B Virus Infection pipeline landscape is provided which includes the disease overview and Chronic Hepatitis B Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Chronic Hepatitis B Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis B Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chronic Hepatitis B Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Hepatitis B Virus Infection Emerging Drugs
Further product details are provided in the report……..
Chronic Hepatitis B Virus Infection: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Hepatitis B Virus Infection drugs segregated based on following parameters that define the scope of the report, such as:
Chronic Hepatitis B Virus Infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis B Virus Infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis B Virus Infection drugs.
Chronic Hepatitis B Virus Infection Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021,” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Chronic Hepatitis B Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Hepatitis B Virus Infection: Overview
Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical and viral parameters that influence disease outcomes. In addition to liver biochemistry, virological markers, and abdominal ultrasonography, non-invasive assessment of liver fibrosis is emerging as an important assessment modality. Long-term nucleos(t)ide-analogue therapy is safe and well tolerated, achieves potent viral suppression, and reduces the incidence of liver-related complications. However, a need to optimise management remains. Promising novel therapies are at the developmental stage.
'Chronic Hepatitis B Virus Infection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Hepatitis B Virus Infection pipeline landscape is provided which includes the disease overview and Chronic Hepatitis B Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Chronic Hepatitis B Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis B Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis B Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis B Virus Infection.
This segment of the Chronic Hepatitis B Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Hepatitis B Virus Infection Emerging Drugs
- AB-729 (GalNAc-RNAi): Arbutus Biopharma
- VIR-2218: Vir Biotechnology
Further product details are provided in the report……..
Chronic Hepatitis B Virus Infection: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Hepatitis B Virus Infection drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Hepatitis B Virus Infection
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chronic Hepatitis B Virus Infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis B Virus Infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis B Virus Infection drugs.
Chronic Hepatitis B Virus Infection Report Insights
- Chronic Hepatitis B Virus Infection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Hepatitis B Virus Infection drugs?
- How many Chronic Hepatitis B Virus Infection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Hepatitis B Virus Infection?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Hepatitis B Virus Infection therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Hepatitis B Virus Infection and their status?
- What are the key designations that have been granted to the emerging drugs?
- Arbutus Biopharma
- Vir Biotechnology
- Ascentage Pharma Group Inc.
- Assembly Biosciences
- Nucorion Pharmaceuticals, Inc.
- Hoffmann-La Roche
- Enyo Pharma
- Qilu Pharmaceutical Co., Ltd.
- Ascletis Pharmaceuticals Co., Ltd.
- Xiamen Amoytop Biotech
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Romark Laboratories L.C.
- Alios Biopharma Inc.
- Antios Therapeutics, Inc
- Jiangsu HengRui Medicine Co., Ltd.
- Enanta Pharmaceuticals
- Janssen Pharmaceuticals
- Gilead Sciences
- Replicor Inc.
- Golden Biotechnology Corporation
- Hepatera Ltd.
- PharmaEssentia
- Chong Kun Dang Pharmaceutical
- Green Cross Corporation
- Aligos Therapeutics
- Sunshine Lake Pharma Co., Ltd.
- Transgene
- Tasly Tianjin Biopharmaceutical Co., Ltd.
- GlaxoSmithKline
- Henlix, Inc
- Ionis Pharmaceuticals, Inc.
- Altimmune, Inc.
- Shanghai HEP Pharmaceutical
- Dong-A ST Co., Ltd.
- Enyo Pharma
- CHA Vaccine Institute Co., Ltd.
- Dicerna Pharmaceuticals, Inc.
- Vaccitech (UK) Limited
- Fujian Cosunter Pharmaceutical Co. Ltd
- Regeneron Pharmaceuticals
- VenatoRx Pharmaceuticals
- ISA Pharmaceuticals
- Finch Therapeutics Group, Inc
- Zhimeng Biopharma
- VBI Vaccines Inc
- GlobeImmune
- AB-729 (GalNAc-RNAi)
- VIR-2218
- APG-1387
- ABI-H2158
- NCO-48
- RO7062931
- EYP001a
- QL-007
- ASC22
- Ypeginterferon alpha-2b
- TQ-A3334
- Nitazoxanide
- JNJ-440
- ATI-2173
- HRS5091
- EDP-514
- JNJ-73763989
- Selgantolimod
- REP 2139-Mg
- Antroquinonol
- Myrcludex B
- P1101
- CKD-390
- GC1102
- ALG-000184
- GLS4
- TG1050
- T101
- ChAd155-hIi-HBV
- Serplulimab
- IONIS-HBVRx
- HepTcell
- Hepalatide
- DA-2802
- EYP001a
- CVI-HBV-002
- DCR-HBVS
- ChAdOx1-HBV
- GST-HG141
- Cemiplimab
- VNRX-9945
- ISA104
- CP101
- ZM-H1505R
- VBI-2601
- GS-4774
Introduction
Executive Summary
Chronic Hepatitis B Virus Infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Ypeginterferon alpha-2b: Xiamen Amoytop Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AB-729: Arbutus Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NCO-48: Nucorion Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Hepatitis B Virus Infection Key Companies
Chronic Hepatitis B Virus Infection Key Products
Chronic Hepatitis B Virus Infection- Unmet Needs
Chronic Hepatitis B Virus Infection- Market Drivers and Barriers
Chronic Hepatitis B Virus Infection- Future Perspectives and Conclusion
Chronic Hepatitis B Virus Infection Analyst Views
Chronic Hepatitis B Virus Infection Key Companies
Appendix
Executive Summary
Chronic Hepatitis B Virus Infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Ypeginterferon alpha-2b: Xiamen Amoytop Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AB-729: Arbutus Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NCO-48: Nucorion Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic Hepatitis B Virus Infection Key Companies
Chronic Hepatitis B Virus Infection Key Products
Chronic Hepatitis B Virus Infection- Unmet Needs
Chronic Hepatitis B Virus Infection- Market Drivers and Barriers
Chronic Hepatitis B Virus Infection- Future Perspectives and Conclusion
Chronic Hepatitis B Virus Infection Analyst Views
Chronic Hepatitis B Virus Infection Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic Hepatitis B Virus Infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic Hepatitis B Virus Infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic Hepatitis B Virus Infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic Hepatitis B Virus Infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
